Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and / or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

The purpose of this study is to test the safety and efficacy of an investigational immunotherapy VGX-3100, in combination with a study device, to treat women with vulvar HSIL (VIN 2 or VIN 3) associated with HPV types 16 and / or 18. VGX-3100 is being assessed as an alternative to surgery with the potential to clear the underlying HPV infection. For more information visit our study website at:
Phase II
Mol. targeted/Immunotherapy/Biologics
Imiquimod Cream, VGX-3100
Alvarez, Ronald
Vanderbilt University


18 Years
Inclusion Criteria:

Women aged 18 and above;

Have high grade squamous intraepithelial lesion (HSIL) of the vulva (VIN2 or VIN3) caused by infection with HPV types 16 and/or 18 confirmed at screening visit;

Exclusion Criteria:

Biopsy-proven differentiated VIN;

Any previous treatment for vulvar HSIL within 4 weeks prior to screening;

Allergy to imiquimod 5% cream or to an inactive ingredient in imiquimod 5% cream;

Pregnant, breastfeeding or considering becoming pregnant within 6 months following the last dose of investigational product;

Immunosuppression as a result of underlying illness or treatment;

Significant acute or chronic medical illness.

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: